Tim has been a Senior Partner at TranScrip since 2013 and has nearly 34 years’ experience in the pharmaceutical industry. Having been US based for more 5 years, working for Aventis and Defined Health, and having established homes on both sides of the Atlantic, he works for TranScrip in both Europe and the US.
Throughout his career Tim has held a number of senior positions in big pharma companies at a national, regional and global level as well as providing independent business consulting services. He has been involved in the commercial assessment, development and launch of many respiratory & allergy compounds, anti-infective, (including antibiotics and antifungals), and novel cardiovascular agents over a period of many years.
He brings his significant experience in the commercial evaluation and development of a number of products in the main stream (asthma, COPD and allergy) and orphan respiratory (Cystic Fibrosis, IPF, Bronchiectasis) spaces, to his role as the Head of TranScrip’s Respiratory team.
Tim also leads TranScrip's Medical Affairs team and within this has guided many commercial assessments of products and/or companies across a wide spectrum of therapeutic areas. These projects have included analysis of the science, clinical development potential, commercial differentiation and pricing and reimbursement which have been used as a firm basis for construction of patient based peak sales forecasts to guide clients as to the potential of assets within the lead indication and alternative opportunities.
In addition to his leadership of the Respiratory and Medical Affairs teams, Tim is also the commercial member of TranScrip’s Infectious disease team, to which he brings experience from working on the commercial evaluation and development of a number of products in the serious infection (multidrug resistant bacterial infections) spaces. He also has moderated a number of scientific advisory boards for clients, been involved in KOL mapping activities and presented at UK workshops and international conferences.
Tim has experience of the entire product life-cycle – from development of target product profiles with research teams, through commercial evaluations of assets prior to phase transitions, pre/peri and post-launch activities at a National and Global level and post patent planning and execution to maximise profitability while maintaining sales volumes.
Tim graduated from Imperial college of Science and Technology with a focus on Zoology and Parasitology.
Before joining TranScrip, he spent 12 years at RPR/Aventis/Sanofi-Aventis in UK, France and the USA. Where he worked variously as the Global Director of Anti-infectives, Global Director New Products (anti-infective and Cardiovascular), Head of Anti-infectives Europe. He later worked for 6 years at Defined Health as the Managing Director Europe, responsible for commercial assessment of assets in the anti-infective, respiratory, CNS and orphan fields, working in both in Europe and the USA. During his time at Defined Health he moderated a number of sessions on the needs and development of antibacterial and respiratory agents at BioEurope Spring, BioPharm America and BioSquare.